Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Healthy male or female subjects.~* Aged 18 to 45 years old.~* Low-density lipoprotein cholesterol \>100 mg/dL (2.59 mmol/L).~Exclusion criteria:~* Subjects with any history or presence of clinically relevant illness.~* Serum triglycerides \>200 mg/dL (2.26 mmol/L) measured after at least 10 hour fasting.~* Use of a medication or nutraceutical in order to alter serum lipids within 4 weeks prior to screening, including but not limited to statins, ezetimibe, fibrates, niacin, or bile acid resins. Use of probucol within 8 weeks prior to screening.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Alirocumab (Type: EXPERIMENTAL): Subcutaneous injection of a single dose of alirocumab, dose level according to ascending dose design
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous injection of a single dose of matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).